Hybrid cell lines were derived which produced monoclonal antibodies directed against gonococcal outer membrane protein IA. One antibody, SMl 01, recognized 24 P.IA-expressing strains out of 25 tested -the rest exhibited relatively less cross-reactivity. Competitive radioimmunoassays revealed that each antibody could effectively inhibit binding of the others, suggesting close proximity of the epitopes recognized. The antibodies were used in assays in vitro to investigate their potential efficacy in protection against gonococcal infection. In a cytotoxicity assay, the antibodies afforded some protection to epithelial cells challenged with gonococci. They were very effective at bactericidal killing in the presence of complement and, in addition, were opsonic for homologous and heterologous strains. The cross-reacting antibody, SMlOl, was one of the most effective in both assays. The results show that the conserved epitope on P.IA recognized by antibody SMlOl is potentially an effective target on the gonococcal surface for immunoprophylaxis.
INTRODUCTION
Extensive interstrain and intrastrain variation of those gonococcal surface antigens which have been associated with virulence, namely pili and outer membrane protein 11, is a major obstacle to the development of an effective vaccine against gonorrhoea (Heckels, 1986) and demonstrates the need for detailed investigation of other more conserved antigens.
The major outer membrane protein, P.1, is not subject to antigenic shift within a strain (Swanson, 1978; Lambden & Heckels, 1979) . Moreover, P.1 appears essential to gonococcal viability since it functions as a porin allowing uptake of essential nutrients (Douglas et al., 1981 ; Lynch et al., 1984) . P.1 may also play an important role in gonococcal virulence by being transferred into the host cell membrane thus perturbing ionic and nutrient balance (Blake & Gotschlich, 1983; Blake, 1985) . These properties as well as the universal occurrence of P.1 and its abundance in the outer membrane suggest that this protein may be a good candidate for incorporation into a gonococcal vaccine.
Although P.1 does not vary within a strain, differences exist between strains which are responsible for serotype specificity (Sandstrom et a/., 1982). However, structural studies have suggested that some domains are more widely shared (Swanson, 1979; Sandstrom et al., 1982) and that only two major classes of P.1 exist (P.IA and P.IB). Previous investigations using monoclonal antibodies directed against P.IB (Fletcher et al., 1986; Virji et al., 1986) revealed a conserved epitope in this group which was recognized by a monoclonal antibody, SM24. This antibody protected tissue culture cells challenged with gonococci expressing protein IB, was bactericidal in the presence of human complement and opsonized all P.IB-expressing strains. These studies indicated that P.IB may be a potentially effective target for immunoprophylaxis of those strains of gonococci expressing the protein. This report describes complementary studies presence of 40 pM-Luminol. A LKB RackBeta scintillation counter was used with the facility to quantify chemiluminescence counts (out of coincidence mode). Other conditions were as described by Virji & Heckels (1986) . A P.11-variant was used for these studies in order to assess the efficacy of antibodies since all P.II+ strains tested greatly stimulated PMN CL in the absence of added antibodies (Virji & Heckels, 1986) .
R E S U L T S
Properties of P . I reactive antibodies As in the previous study (Fletcher et al., 1986) with P.IB monoclonal antibodies, the aim was to obtain antibodies which recognized widely distributed epitopes on P.IA. The immunization schedule and screening procedures used selected four such antibodies. Table 1 shows some properties of these antibodies. Dot blotting with iodinated purified anti bodies against whole-cell lysates showed that the reactivity of the antibodies was widespread within P.IA-expressing strains (Table 2 ). Three antibodies, SM100, 102 and 103, showed very similar patterns of reaction against 64% of P.IA strains. The fourth antibody, SMlO1, recognized 96% of P.IA strains. That reaction of these antibodies was restricted to P.IA-expressing gonococci alone was shown by dot blotting against other organisms (Table 2) .
Competitive radioimmunoassay
In order to investigate the relationship of the epitopes recognized by the antibodies on P.IA, competitive binding assays were done. Each unlabelled antibody effectively displaced all labelled antibodies when present at eightfold excess (Table 3) . In contrast, anti-P.111 antibodies when present at the same concentration exhibited little or no inhibition of binding of P.IA antibody. However, one antibody, SM50, did show a significant inhibition when present at gross excess (80-fold).
Protection of epithelial cells
Chang conjunctiva epithelial cells used in these studies show susceptibility to different gonococcal strains in a dose-dependent manner. In the current study. one P.IA-expressing strains, SU62, was chosen to demonstrate the efficacy of antibodies to P.IA in protection of host cells against gonococcal invasion. Ascitic fluids containing antibodies used at a dilution of 1 : 100 significantly decreased the virulence of gonococci at a challenge dose of 1-7 x lo5 : thus viability of host cells was increased from < 20% in the absence to > 50% in the presence of antibodies (Table 4) . However, this effect was apparent only over a limited range of gonococcal c.f.u. used in challenge as shown in Fig. 1 which demonstrates the typical results for two antibodies.
Bactericidal eflect of anti-P. IA monoclonal antibody Several P.IA-expressing strains were tested for their susceptibility to killing by normal human serum. In the presence of 10% fresh serum used as the complement source, different strains exhibited different degrees of resistance to killing. However, all strains were totally killed when the cross-reacting antibody, SMlOl, was also present in addition to complement. One strain, SU93, was chosen for detailed studies with all antibodies since, as well as being resistant to normal serum, it reacted with all type-specific monoclonal antibodies. Results presented in Fig.  2 show that all the antibodies were bactericidal for this strain.
Opsonic eflect of anti-P . IA monoclonal antibodies Most fresh clinical isolates express P.11 and stimulate PMN chemiluminescence in the absence of added antibody. A P.11-variant of strain SU70 selected on agar was used to evaluate the opsonic effect of the cross-reacting antibody, SM101. This antibody was highly opsonic as demonstrated by the extent of the CL increase for the P.II+ parent as well as P.11-variant (Fig.  3) . The type-specific antibodies were also opsonic for P.11-variant of SU70 (Fig. 4) . (-) or without (---) the cross-reacting antibody SM101. A, P.II+ natural isolate SU70; 0 , P.11-variant of SU70. Antibodies were present as ascitic fluids at 1 : 300 dilution. 
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DISCUSSION
The two molecular forms of the major outer membrane protein, P.IA and P.IB, are structurally and antigenically distinct. Their antigenic diversity has been the basis of classification of gonococci into the WI and WII/WIII serogroups (Sandstrom & Danielsson, 1980) . Serogroup WI strains were shown by peptide mapping to express P.IA and WII/WIII to express P.IB (Sandstrom et al., 1982) . Proteolytic treatment of gonococci reveals that the orientation of two proteins within the outer membrane is radically different. Most of the P.IA molecule is contained within the membrane, with only a short terminal portion exposed on the surface, whereas P.IB molecules have their two terminal regions located in the membrane and a relatively large central portion exposed on the surface (Barrera & Swanson, 1984) . Despite their structural differences, the two proteins carry out the same important functional role of porins, allowing selective uptake of nutrients into the bacterial cell (Lynch et al., 1984) . In addition, Blake & Gotschlich (1983) have suggested that each protein may be involved in the pathogenesis of gonococcal infection, being transferred into the eukaryotic host membrane possibly causing a perturbation which acts as the trigger for uptake of gonococci by endocytosis. Thus, P.1 appears to play central roles in the maintenance of gonococcal viability and in virulence, which ensures its permanent expression on the bacterial surface. These properties and its relatively conserved nature within each group makes P.1 an attractive candidate for a gonococcal vaccine.
In considering P.1 as a potential vaccine component, however, the two distinct forms need to be considered separately. Despite the numerous serologically useful monoclonal antibody reagents that have been raised in several laboratories against these proteins, none has been shown to cross-react between the two groups, suggesting that either no surface-exposed epitopes are shared or that these are immunorecessive. Previous reports (Fletcher et al., 1986; Virji et al., 1986) have described studies of epitope distribution on P.IB molecules and the potential efficacy of both type-specific and cross-reacting monoclonal antibodies in protection against gonococcal infection using in vitro model systems. Epitope distribution studies suggested that a conserved epitope recognized by one antibody (SM24) was the most superficially located and therefore easily accessible. This antibody proved to be the most effective in protection of epithelial cells against the cytotoxic effect of live organisms and, in addition, mediated complement bactericidal activity and opsonized bacteria for phagocytosis by PMN.
The current study has similarly assessed the epitopes on P.IA. Screening of many antibodysecreting hybridoma yielded only four stable clones producing anti-P.IA monoclonal antibodies. Other workers have reported a similar paucity of separate immunogenic epitopes on this protein (Knapp et al., 1984; Tam et al., 1983; Sandstrom et al., 1985) , which may result from its limited exposure on the gonococcal surface (Barrera & Swanson, 1984) . One antibody, SM101, crossreacted with 96% of P.IA-expressing strains while the remainder reacted with 64%. Competitive radioimmunoassays showed total inhibition of binding of each antibody by all the heterologous competitors suggesting that the epitopes recognized may be very closely positioned, overlapping or perhaps even identical. However, since SMlOl (isotope y 2b) recognizes many more strains compared with the other antibodies, this epitope at least must be distinct from the rest. The three type-specific antibodies were of the same isotype, y 3 ; however, each antibody exhibited significant differences in the biological assays. The differences cannot be due to the variation in binding parameters since all bound to their antigenic sites with similar avidities and to the same relative number of binding sites. The data seem to suggest clustering of closely positioned immunogenic sites which may be partially overlapping.
The most significant observation is that the cross-reacting antibody, SMlOl, was the most effective in both bactericidal and opsonic assays. It also protected tissue-culture cells at certain challenge doses of gonococci. However, the protection was much lower than that observed for P.IB antibodies (Virji et al., 1986) , which may reflect a greater ability of P.IA to transfer into eukaryotic cell membranes (Blake, 1985) . The relative importance of the effects of inhibition of invasion, phagocytosis and bactericidal killing in immunity to uncomplicated gonococcal infection are unknown. However, bactericidal and opsonic anti bodies may be particularly important in prevention of complicated infection and Buchanan et al. (1980) have reported that bactericidal antibodies directed against P.1 elicit serotype protection against gonococcal salpingitis. A putative P.1 vaccine should clearly protect against most, if not all, gonococcal serotypes regardless of whether they are P.IA or P.IB. Monoclonal antibodies SM24 and SMlOl together recognize 94% of strains so far tested and protect in the in vitro model systems. Thus immunization strategies designed to boost the natural immune response to only two antigenic determinants can be predicted to provide effective immunity to a large number of gonococcal strains.
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